COVID-19 Biological Samples Collection
COLCOV19-BX
Biological Samples Collection From Patients and Caregivers Treated at Bordeaux University Hospital for Asymptomatic and Symptomatic Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) Infection (COVID-19).
1 other identifier
observational
2,000
1 country
1
Brief Summary
The coronavirus disease 2019 (COVID-19) outbreak is now considered as a public health emergency of international concern by the World Health Organization. In the context of the health emergency, research on the pathogen (the SARS-CoV-2 coronavirus), the disease and the therapeutic care is being organized. Research projects require the use of biological samples. This study aims at setting up a collection of biological samples intended for application projects in any discipline. The main objective of the study is to collect, process and store biological samples from patients and caregivers infected with SARS-CoV-2 (COVID-19) at the biological ressources center of the Bordeaux University Hospital.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2020
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 30, 2020
CompletedFirst Posted
Study publicly available on registry
April 2, 2020
CompletedStudy Start
First participant enrolled
April 2, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2025
CompletedNovember 8, 2023
November 1, 2023
4.5 years
March 30, 2020
November 7, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
COVID-19 desease description
From blood samples: protein levels, whole genome sequence, transcriptomic analysis data. From upper respiratory samples: protein levels, virus transcriptomic analysis data. From stool: microbiota analysis data. From urine: protein level.
Inclusion visit (Day 1)
COVID-19 desease description
From blood samples: protein levels.
Day 30 to 90
Study Arms (1)
COVID-19 infected patients
Interventions
collection of whole blood samples, urine and stool samples, upper respiratory samples, post-mortem biopsies
Eligibility Criteria
Patients / caregivers treated at Bordeaux University Hospital for asymptomatic or symptomatic infection by SARS -CoV-2.
You may qualify if:
- Patients / caregivers treated at Bordeaux University Hospital for asymptomatic or symptomatic infection by SARS -CoV-2
- men and women, adults and minors as well as pregnant or breastfeeding women
- patients who died following infection with SARS-CoV-2 (specific criterion for post-mortem biopsies)
- Be affiliated with or beneficiary of a social security scheme
- Free and informed consent obtained and signed by the patient
You may not qualify if:
- Under guardianship or curatorship
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Centre Hospitalier Universitaire de Bordeaux
Bordeaux, 33076, France
Related Publications (1)
Garcia G, Labrouche-Colomer S, Duvignaud A, Clequin E, Dussiau C, Tregouet DA, Malvy D, Prevel R, Zouine A, Pellegrin I, Goret J, Mamani-Matsuda M, Dewitte A, James C. Impaired balance between neutrophil extracellular trap formation and degradation by DNases in COVID-19 disease. J Transl Med. 2024 Mar 7;22(1):246. doi: 10.1186/s12967-024-05044-7.
PMID: 38454482DERIVED
Biospecimen
Whole Blood Sample Upper respiratory sampling Urine and stool collection Post mortem biopsies
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 30, 2020
First Posted
April 2, 2020
Study Start
April 2, 2020
Primary Completion
October 1, 2024
Study Completion
April 1, 2025
Last Updated
November 8, 2023
Record last verified: 2023-11
Data Sharing
- IPD Sharing
- Will not share